A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Nave Patients With Type 2 Diabetes

Status:
NOT_YET_RECRUITING

Trial end date:
2027-07-30

Target enrollment:

Participant gender:

This study will compare the effect and safety of cofrogliptin (HSK7653) with acarbose among people with type 2 diabetes

Haisco Pharmaceutical Group Co., Ltd.

Acarbose